Recent research advances in the development of Dabie Banda virus vaccines

Severe fever with thrombocytopenia syndrome (SFTS) is a newly identified tick-borne viral hemorrhagic fever caused by Dabie Banda virus (DBV). The virus was first discovered in eastern China in 2009 and is now considered an infectious disease with a mortality rate ranging from 6.3% to 30%. The best...

Full description

Saved in:
Bibliographic Details
Published in:PLoS neglected tropical diseases 2024-08, Vol.18 (8), p.e0012411
Main Authors: Yu, Chenyang, Lin, Yuxiang, Dai, Yixin, Wu, Bingan, Qi, Zhongtian, Qian, Xijing
Format: Article
Language:English
Subjects:
Animals
Biology and Life Sciences
Humans
Medicine and Health Sciences
Pharmaceutical research
Phlebovirus - genetics
Phlebovirus - immunology
Prevention
Review
RNA virus infections
Severe Fever with Thrombocytopenia Syndrome - immunology
Severe Fever with Thrombocytopenia Syndrome - prevention & control
Tick-borne diseases
Vaccine Development
Vaccines, Attenuated - immunology
Vaccines, DNA - immunology
Vaccines, Subunit - immunology
Viral vaccines
Viral Vaccines - immunology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe fever with thrombocytopenia syndrome (SFTS) is a newly identified tick-borne viral hemorrhagic fever caused by Dabie Banda virus (DBV). The virus was first discovered in eastern China in 2009 and is now considered an infectious disease with a mortality rate ranging from 6.3% to 30%. The best strategy for controlling SFTS is to develop effective vaccines. However, no approved vaccines are currently available to prevent this disease, despite the number of extensive and in-depth studies conducted on DBV in the past few years. This review focuses on the structure of DBV and the induced host immune responses which are the fundamental factors in vaccine development, and thoroughly summarizes the current research progress on DBV vaccines. The developing DBV vaccines include protein subunit vaccines, live attenuated vaccines, recombinant virus vector vaccines, and DNA vaccines. At present, almost all candidate vaccines for DBV are in the laboratory development or preclinical stages. There remain challenges in successfully developing clinically approved DBV vaccines.
ISSN:1935-2735
1935-2727
1935-2735
DOI:10.1371/journal.pntd.0012411